Live
- Delhi HC dismisses anticipatory bail plea of ex-IAS trainee officer Puja Khedkar
- Untouched Goa Beaches You Must Visit in January
- Muzigal launches its State-of-the-art Music Academy in Nallagandla, Hyderabad
- Thoughtful Christmas Gifts for Every Loved One
- South Korea: Finance minister silent on martial law probe amid speculation on acting president's role
- Karnataka Minister Laxmi Hebbalkar Vows To Pursue Justice Against CT Ravi
- Stands By Vijayaraghavan Amid Row Over Remarks On Gandhis
- Karnataka Legislative Council Chairman Denies Recording Controversial Exchange
- Lexus India to Redefine Luxury Mobility at Bharat Mobility Global Expo 2025
- Hindustan Zinc Supported Farmers Achieve INR 5 Cr Revenue Through Five Farmer Produce Organizations
Hope to resolve issues faced by Indians vaccinated with Covishield travelling to EU soon: Poonawalla
Serum Institute of India CEO Adar Poonawalla (Photo | PTI)
Vaccine major Serum Institute of India chief executive officer Adar Poonawalla on Monday said he has taken up the issues faced by Indians who have taken the Covishield jab travelling to the European Union at highest levels and hoped to resolve them soon.
NEW DELHI: Vaccine major Serum Institute of India chief executive officer Adar Poonawalla on Monday said he has taken up the issues faced by Indians who have taken the Covishield jab travelling to the European Union at highest levels and hoped to resolve them soon.
Covishield is the Oxford University-AstraZeneca vaccine manufactured in India by the Pune-based vaccine maker.
"I realise that a lot of Indians who have taken Covishield are facing issues with travel to the EU, I assure everyone, I have taken this up at the highest levels and hope to resolve this matter soon, both with regulators and at a diplomatic level with countries," Poonawalla said in a tweet.
As of now European Union (EU) recognises Vaxzevria (previously COVID-19 Vaccine AstraZeneca, Oxford).
The other vaccines approved by the European Medicine Agency are Comirnaty by BioNTech-Pfizer, Moderna and Janssen (Johnson & Johnson).
